Company Analysis

ImmuCell Corporation (ICCC)

Nasdaq: ICCC · In Vitro & In Vivo Diagnostic Substances · Portland, ME · filing with the SEC since 1995
Grade5.3
◀ Past 4.8● Present 5.8▶ Future 4.9
1 est.

Who runs ImmuCell Corporation

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Te Boekhorst Paul Francis Olivier
President and CEO. First filing Nov 2025, latest Jun 22, 2026, 3 filings in all.
Officers reporting now
4
of 12 people with a filing in the last fifteen months
Directors reporting now
8
17 people on the record since 2006
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Te Boekhorst Paul Francis OlivierPresident and CEONov 2025Jun 22, 2026none
Brockmann Bobbi JoVP of Sales and MarketingApr 2011Apr 14, 2026none
Brigham Michael FPresident & CEOMar 2006Mar 24, 2026none
Fiori Timothy CChief Financial OfficerApr 2025Jan 29, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Dimarco AnthonydirectorApr 2026Apr 23, 2026none
Guillemette GillesdirectorApr 2026Apr 23, 2026none
Basse Gloria FdirectorJun 2021Apr 16, 2026none
Tomsche David ScottdirectorDec 2006Apr 16, 2026none
Turner Kathy VdirectorApr 2026Apr 16, 2026none
Wainman Paul RdirectorApr 2014Apr 16, 2026none
Gathagan Bryan K.directorJun 2023Apr 14, 2026none
Rosgen Steven T.directorFeb 2018Apr 14, 2026none
Earlier names on the record7, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton ICCC · research, not advice